J&J’s New Innovation Centers Test Immersion Theory Of Access
Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?
You may also be interested in...
We’ve got this year’s winners for the Deals Of The Year, as well as this week’s deal news from Forest/Aptalis, Royalty Pharma, Biogen Idec/Sangamo and a string of early deals from Johnson & Johnson.
The healthcare conglomerate has been testing out-of-the-box ways to address current key challenges for its stakeholders, namely improving the patient experience, reducing the cost-burden to the health care system, and ultimately enhancing the marketplace in which it sells its products.
The third of Johnson & Johnson’s four Innovation Centers, designed to give the behemoth company access and proximity to early-stage scientific innovation, opened June 27 in Boston. Concurrently, the company backed two VC-funded young start-ups , as well as a hospital alliance and a laboratory initiative.